Needham & Company LLC Reaffirms Hold Rating for Inogen (NASDAQ:INGN)

Needham & Company LLC reaffirmed their hold rating on shares of Inogen (NASDAQ:INGN) in a research report report published on Thursday,Benzinga reports.

Separately, StockNews.com lowered shares of Inogen from a “buy” rating to a “hold” rating in a research note on Friday, December 20th.

Inogen Stock Down 4.6 %

Shares of INGN stock opened at $11.95 on Thursday. The company has a 50-day moving average of $9.79 and a two-hundred day moving average of $10.11. Inogen has a 1-year low of $5.82 and a 1-year high of $13.33.

Inogen (NASDAQ:INGN) last announced its earnings results on Thursday, November 7th. The medical technology company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.26. The company had revenue of $88.83 million during the quarter, compared to analyst estimates of $83.68 million. Inogen had a negative net margin of 15.89% and a negative return on equity of 27.38%. During the same quarter last year, the firm posted ($1.97) earnings per share. As a group, analysts expect that Inogen will post -1.73 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in INGN. Quarry LP purchased a new position in Inogen in the third quarter worth approximately $59,000. Verition Fund Management LLC purchased a new position in Inogen in the third quarter worth approximately $106,000. Virtu Financial LLC purchased a new position in Inogen in the third quarter worth approximately $111,000. Paloma Partners Management Co purchased a new position in Inogen in the third quarter worth approximately $126,000. Finally, Centiva Capital LP purchased a new position in Inogen in the third quarter worth approximately $138,000. Hedge funds and other institutional investors own 89.94% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.